| [1] |
谢玲玲, 林荣春, 林仲秋. 2017 NCCN《子宫肿瘤临床实践指南》简介[J]. 中国实用妇科与产科杂志, 2017, 33(5): 480-484. DOI: 10.19538/j.fk2017050112.
|
| [2] |
Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(1): 17-48. DOI: 10.3322/caac.21763.
|
| [3] |
Post CCB, Westermann AM, Bosse T, et al. PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer[J]. Crit Rev Oncol Hematol, 2020, 152: 102973. DOI: 10.1016/j.critrevonc.2020.102973.
|
| [4] |
Legge F, Restaino S, Leone L, et al. Clinical outcome of recurrent endometrial cancer: analysis of post-relapse survival by pattern of recurrence and secondary treatment[J]. Int J Gynecol Cancer, 2020, 30(2): 193-200. DOI: 10.1136/ijgc-2019-000822.
pmid: 31792085
|
| [5] |
Tronconi F, Nero C, Giudice E, et al. Advanced and recurrent endometrial cancer: state of the art and future perspectives[J]. Crit Rev Oncol Hematol, 2022, 180: 103851. DOI: 10.1016/j.critrevonc. 2022.103851.
|
| [6] |
Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and paclitaxel for advanced endometrial cancer: final overall survival and adverse event analysis of a phase Ⅲ trial (NRG oncology/GOG0209)[J]. J Clin Oncol, 2020, 38(33): 3841-3850. DOI: 10.1200/JCO.20.01076.
pmid: 33078978
|
| [7] |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasmsr (version 1.2024)[EB/OL]. [2023-08-10]. https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf.
|
| [8] |
Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated and microsatellite-instable endometrial cancers with neoantigen load, number of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1[J]. JAMA Oncol, 2015, 1(9): 1319-1323. DOI: 10.1001/jamaoncol.2015.2151.
pmid: 26181000
|
| [9] |
O'Malley DM, Bariani GM, Cassier PA, et al. Pembrolizumab in patients with microsatellite instability-high advanced endometrial cancer: results from the KEYNOTE-158 study[J]. J Clin Oncol, 2022, 40(7): 752-761. DOI: 10.1200/JCO.21.01874.
|
| [10] |
Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase ⅡKEYNOTE-158 study[J]. J Clin Oncol, 2020, 38(1): 1-10. DOI: 10.1200/JCO.19.02105.
pmid: 31682550
|
| [11] |
Oaknin A, Tinker AV, Gilbert L, et al. Clinical activity and safety of the anti-programmed death 1 monoclonal antibody dostarlimab for patients with recurrent or advanced mismatch repair-deficient endometrial cancer: a nonrandomized phase 1 clinical trial[J]. JAMA Oncol, 2020, 6(11): 1766-1772. DOI: 10.1001/jamaoncol.2020.4515.
|
| [12] |
Eskander RN, Sill MW, Beffa L, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer[J]. N Engl J Med, 2023, 388(23): 2159-2170. DOI: 10.1056/NEJMoa2302312.
|
| [13] |
Shen G, Zheng F, Ren D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development[J]. J Hematol Oncol, 2018, 11(1): 120. DOI: 10.1186/s13045-018-0664-7.
|
| [14] |
Shan YL, Zhong CJ, Ni Q, et al. Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model[J]. J Clin Oncol, 2021, 39(15 suppl): 2581. DOI: 10.1200/JCO.2021.39.15_suppl.2581.
|
| [15] |
Makker V, Colombo N, Casado Herráez A, et al. Lenvatinib plus pembrolizumab for advanced endometrial cancer[J]. N Engl J Med, 2022, 386(5): 437-448. DOI: 10.1056/NEJMoa2108330.
|
| [16] |
Wei W, Ban X, Yang F, et al. Phase Ⅱ trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer[J]. J Immunother Cancer, 2022, 10(5): e004338. DOI: 10.1136/jitc-2021-004338.
|
| [17] |
Uno K, Yoshihara M, Tano S, et al. Proton beam therapy for the isolated recurrence of endometrial cancer in para-aortic lymph nodes: a case report[J]. BMC Womens Health, 2022, 22(1): 375. DOI: 10.1186/s12905-022-01961-1.
pmid: 36104694
|
